by CML Advocates | Jul 29, 2022 | CML-CAB
CML-CAB Meetings: Based on the proven ECAB model implemented by the HIV patient community and EATG for more than a decade, the first CML-CAB was held in May 2016. Since then, we have carried out 14 CML Community Advisory Boards in 24 sessions (2016-2024). 14 CML-CABs...
by CML Advocates | Jul 29, 2022 | CML-CAB
CML-CAB Objectives & Strategy The CML-CAB objectives are: Providing researchers, academics, government, policy makers, authorities and the pharmaceutical industry with advice and input on different issues that impact on patients’ lives Promoting...
by Marija | Jul 29, 2022 | CML-CAB
CAB Team Members Chairs & Management Western Europe & Israel Eastern Europe North Amrica Latin America Africa & Middle East Asia Pacific CML-CAB Chairs Bahija Gouimi (Morocco) CML advocacy years: 22No. of CMLHZ attended: 16 Gerald Clements (USA) ...
by Marija | Jul 29, 2022 | CML-CAB
How do CABs work? CML-CAB invites participants from the companies CML-CAB sets the agenda for a two-way dialogue and pick the topics that are most meaningful to us CML-CAB respects confidentiality to have a trusted and open dialogue CML-CAB reports to...
by Marija | Jul 29, 2022 | CML-CAB
Why CML-CABs? Here at CML-CAB, we know that research is key towards better outcomes, but often the trials are done without patient input, do not deliver on unmet needs, do not deliver patient-relevant data (e.g. PRO, QoL), are run in the wrong countries and do not...
by Marija | Jul 29, 2022 | CML-CAB
What are CML CABs? Our Community Advisory Board (CAB) is a diverse, global panel of 25 leading patient advocates from all world regions. Established in 2016 based on the HIV model, we have set up this CAB of patient representatives to act as a link between the...